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Review
Epidemiology of CA
Out‑of‑hospital cardiac arrest in 2014: incidence, outcome 
and disparities
Peter Kudenchuk Out-hospital-cardiac arrest (OHCA) 
remains a common public health problem. Each year, car-
diac arrest claims more than 424,000 lives in the United 
States, 300,000 lives in Europe, and upwards of 3.7 million 
lives worldwide. Resuscitation is typically conducted in 
accordance with a uniform algorithmic approach embod-
ied in the “chain of survival” which emphasizes the impor-
tance of early activation of emergency medical services, 
prompt CPR, rapid defibrillation, advanced cardiac life 
support and post-cardiac arrest care. This, in fact might be 
said to be the only uniform aspect of cardiac arrest, which 
is otherwise riddled with disparities. The first of these 
disparities lies in how few patients who are successfully 
resuscitated from cardiac arrest ultimately survive to hos-
pital discharge. In Seattle, approximately 60 % of patients 
in whom cardiac arrest presents as ventricular fibrillation 
(VF) are successfully resuscitated and admitted to hospital; 
yet only about half of these (30 %) typically survive to hos-
pital discharge. When cardiac arrest presents as asystole or 
pulseless electrical activity (PEA), outcomes are strikingly 
worse: only 20–30 % of such patients are successfully 
resuscitated, and an even smaller proportion of these, as 
few as 2 in 10—ranging from 2 to 5 % of patients, survive 
to hospital discharge [1].
A second disparity lies in the changing incidence of 
rhythms that precipitate cardiac arrest. In Seattle dur-
ing the decade of the 1970s, VF accounted for approxi-
mately 60 % of all out-of-hospital cardiac arrests treated 
by emergency medical services (EMS), whereas the 
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remainder of acute rhythm presentations were equally 
divided between asystole and PEA. In the ensuing years, 
the proportion of cardiac arrests caused by VF has 
declined to 25–30 % of cases, such that now asystole and 
PEA represent the most common presenting rhythms. 
Extrapolating these incidence data from Seattle to the 
United States census, the annual rate of cardiac arrest due 
to ventricular fibrillation declined from about 85 persons 
per 100,000 in 1980 to 38/100,000 in 2000 [1]. Data from 
the Resuscitation Outcomes Consortium estimated a fur-
ther decline in the incidence of VF cardiac arrest to 17.4 
adults/100,000 in 2011 [2]. These statistics, coupled with 
the known worse survival prognosis of patients in whom 
cardiac presents as a non-shockable rhythm, pose a new 
and major challenge for the present and future treatment 
of this emerging “new wave” of cardiac arrest victims.
A third disparity lies in the marked differences in out-
come from cardiac arrest between communities across 
Europe and the United States. For cardiac arrest due to 
VF, survival can vary significantly between major cities by 
many-fold (Fig. 1) [3–5]. To some extent, such differences 
in outcome are explained by inaccuracies in record keep-
ing. For example, few communities actually report their 
incidence of cardiac arrest and outcome [6]. And even 
among those that do, complete capture of all cases of car-
diac arrest and the reliability of their survival data can 
be questionable, accounting for some of the variability 
in outcomes that are reported. This said, record keeping 
alone does not entirely explain these discrepancies. Iden-
tifying and targeting remediable causes of differences in 
survival between communities is imperative if we are 
to assure citizens that they are comparably “safe” from 
death by cardiac arrest in whatever locale they call home. 
Clinical factors that are known to account for differences 
in survival outcome from cardiac arrest include patient 
characteristics—such as age, gender, and co-morbidities; 
and by the circumstances of the arrest—such as whether 
witnessed by bystanders, the location of its occurrence, 
and by the presenting arrest rhythm. Most would regard 
these as “factors of fate” and as such not alterable. Con-
versely, the components of prehospital emergency medi-
cal care, including rapid dispatch, dispatcher-assisted 
CPR, EMS training and time-to-treatment, are all poten-
tially correctable factors. Targeting these aspects of pre-
hospital care affords an opportunity to change outcome 
for the better after cardiac arrest. Among these, perhaps 
the one that can be most readily and immediately imple-
mented is high-performance CPR.
High-performance CPR consists of training with 
meticulous attention to the details of performing CPR to 
the best known prescribed parameters of chest compres-
sion rate, depth, full chest recoil, and minimized inter-
ruptions, and applying strict compliance standards (e.g. 
a compression fraction of no less than 85  %) for their 
performance during resuscitation. In addition to striv-
ing for “letter perfect” CPR performance, it also involves 
a system of accountability, whereby feed-back of CPR 
performance derived from a review of recordings of field 
resuscitations is consistently conveyed back to providers 
for further possible improvement. Deploying such a high-
performance CPR protocol in King County, Washington, 
starting in 2005 resulted in a significant improvement in 
survival from both cardiac arrest due to ventricular fibril-
lation (Fig.  2) [7], as well as asystole/PEA [8] that has 
been sustained in the ensuing years. The attractiveness of 
high-performance CPR is that it is relatively inexpensive 
to deploy (can be easily added to existing EMS training 
programs), does not require special equipment (hands 
Fig. 1 Survival to hospital discharge from out‑of‑hospital ventricular 
fibrillation in various communities outside the United States
Fig. 2 The impact of instituting high‑performance CPR in King 
County, Washington, in 2005 on survival from witnessed out‑of‑
hospital cardiac arrest due to ventricular fibrillation
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only), and has demonstrated that it can improve outcome 
for virtually all presentations of cardiac arrest.
While many of the identified disparities in cardiac 
arrest will continue to pose challenges for its manage-
ment, a focus on improving systems-of-care, particularly 
deployment of high-performance letter-perfect CPR, 
offers the promise of a practical intervention that can be 
implemented immediately and an effort that promises to 
improve survival outcomes in any community.
Effectiveness of rapid response systems for prevention 
of cardiac arrest
Claudio Sandroni Despite the immediate availability of 
qualified life support, the outcome of in-hospital cardiac 
arrest (IHCA) remains poor. Survival to discharge after 
IHCA rarely exceeds 20 % [9] and it has remained stable 
in the last 25 years (Fig. 3). Rapid response systems (RRS) 
have been established to prevent IHCA in non-critical 
care areas of the hospital [10]. Those systems are based 
on timely detection of deteriorating patients by the ward 
personnel (the afferent limb of the system), who will there-
fore summon a medical emergency team (MET; the effer-
ent limb of the system), whose roles are to stabilize the 
patient in the ward or escalate the level of care. Although 
the theory underlying RRS is compelling, there is no defi-
nite evidence that their implementation improves patient 
outcome. The major problem in evaluating the effective-
ness of RRS is the choice of the outcome measure.
The first endpoint for a study addressing the effective-
ness of RRS could be the rates of unexpected cardiac 
arrests occurring outside intensive care units (ICUs), 
that is, the rates of cardiac arrest occurring in ward 
patients for whom there is no do-not-attempt-resusci-
tation (DNAR) order. This endpoint, however, is poten-
tially biased by the fact that one of the tasks of METs is to 
identify ward patients for whom a resuscitation would be 
inappropriate. Therefore, part of the observed reduction 
in the rate of unexpected cardiac arrest after the imple-
mentation of a RRS is because the fraction of expected 
cardiac arrests is increased by placement of a DNAR 
order.
Another endpoint for measuring RRS effectiveness is 
the reduction of unplanned ICU admissions. The ration-
ale is that the introduction of RRS should increase the 
number of ICU admissions that are planned early, before 
further deterioration occurs, and decrease those occur-
ring as emergency admissions after resuscitation from 
cardiac arrest. This model has been indirectly demon-
strated for ICU admissions from Emergency Depart-
ment [11] where an earlier transfer to ICU has been 
demonstrated to decrease both ICU and hospital mor-
tality. However, this is not always the case with RRS. In 
one large American before-and-after study [12] in which 
almost half of the MET interventions resulted in an ICU 
admission, the implementation of the RRS was followed 
by a reduction of non-ICU codes but it did not translate 
in a reduction of hospital mortality. In that study, mor-
tality in patient transferred from ward to ICU was very 
high, and problems of patient selection, appropriateness 
and timeliness of ICU transfer have been advocated to 
explain these results.
The third, and most comprehensive endpoint for RRS 
effectiveness is hospital mortality. Unfortunately, meta-
analyses of available evidence on this endpoint showed 
conflicting results, with some studies showing benefit 
and others showing no or only non-significant reduc-
tion of hospital mortality after RRS implementation [13]. 
Moreover, the quality of evidence is relatively low, with 
almost all studies having a before-and-after design, which 
make them prone to bias due to secular trends unrelated 
to the study intervention or to changes in hospital case 
mix, a variable which is difficult to adjust for.
The ultimate strategy for assessing RSS effectiveness 
would be a randomized trial with concurrent cohorts, 
which would allow the investigators to control for most 
possible confounders. However, this solution is ham-
pered by both ethical and implementation issues. Ran-
domization at individual patient level for interventions 
which are commonly believed to be beneficial would in 
fact be ethically questionable. Cluster randomization is 
ethically acceptable, but difficult to implement because 
RRS intervention cannot be blinded, and contamination 
between the two study arms would be unavoidable, as did 
actually occur in the MERIT trial, the only randomized 
study conducted since now on RRS [14]. Another major 
implementation issue in that trial, as in general for RRS, 
was an afferent limb failure [15], due to an incomplete 
compliance of the ward personnel with the MET calling 
criteria.
Fig. 3 The 25‑year trend of rates of survival to discharge after resus‑
citation from in‑hospital cardiac arrest in 100 observational studies, 
1985–2010
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A final issue is reproducibility. The vast majority of 
studies have been made in UK or Australian–New Zea-
land systems, a minority of studies have been conducted 
in US and only very few studies have been conducted in 
other World areas as Continental Europe or Asia. The 
effectiveness of an RRS depends on the nature and the 
quantity of the urgent, unmet patients’ needs in general 
wards. This model may not work in places where the 
severity of patients in general wards, the education of the 
ward personnel or the resource availability is different 
from that of places where this model was developed.
In summary, there are different ways of measuring 
the effectiveness of RRSs. The major include the rate of 
unexpected CA outside ICU, the rate of unplanned ICU 
admissions, and hospital mortality. All these outcome 
measures have limitations and are prone to bias. The level 
of evidence supporting the effectiveness of RRSs is rela-
tively low and almost all studies have a before-and-after 
design. Despite the ethical and implementation difficul-
ties, high-quality randomized trials are warranted to reli-
ably assess the effectiveness of RRS.
Pre‑hospital management
CPR quality has a deep impact
Hendrik Drinhaus and Bernd Böttiger Despite enormous 
efforts in recent years to improve quality of cardiopulmo-
nary resuscitation (CPR) by the development of new CPR-
guidelines and to enhance post-resuscitation care particu-
larly by the introduction of mild therapeutic hypothermia 
and early coronary intervention, survival rates after OHCA 
remain unsatisfyingly low in many countries. As a prereq-
uisite for successful post-resuscitation care on the Intensive 
Care Unit, high-quality CPR must be started as early as pos-
sible. As advanced life support (ALS) by emergency medi-
cal services (EMS) can only be expected to be commenced 
several minutes after OHCA, timely initiation of basic life 
support (BLS) by lay bystanders is crucial to ensure a timely 
perfusion of the brain and other vital organs. Sufficient per-
fusion can only be obtained by high-quality CPR. Hence, 
it is vital to increase the percentage of bystander-CPR and 
to improve the quality of both BLS and ALS. According to 
the German Resuscitation Registry, bystander-CPR is per-
formed in less than 20 % of OHCA cases [16], as opposed 
to 50 % or more in Scandinavian countries. Large-scale 
programmes raising public awareness of cardiac arrest 
and CPR as well as providing hands-on training in BLS 
are a promising tool to improve survival after OHCA. In 
a national initiative that included CPR-training as early as 
in primary school, telephone guidance to CPR by EMS-
dispatchers, and distribution of automated external defibril-
lators (AED) in Denmark [17], the rate of bystander-CPR 
could be increased from 21 to 45 % and 1-year survival 
raised from 3 to 10 % during the intervention period. It is 
worth noting that the percentage of AED-use increased only 
from 1 to 2 %, which implies that the impressive improve-
ment of outcomes of OHCA patients is rather due to prompt 
basic life support (as well as improved post-resuscitation 
care) than to AEDs. Similar initiatives are now being under-
taken in Germany. Once CPR is started, its high quality is 
decisive for outcome. Compression depth must be sufficient 
(5–6 cm), frequency appropriate (100–120/min.), the chest 
must be released between compressions and interruptions 
of chest compressions must be kept as short as possible. 
Several studies have shown an association between these 
factors and survival [18–20]. During ALS by EMS-person-
nel, further variables are part of CPR quality: in the OHCA-
setting, automated chest compression devices have failed 
to prove superiority to manual CPR. There is still much 
debate on airway management and staffing of ambulance 
cars. Retrospective studies have shown higher survival rates 
in patients who received endotracheal intubation (ETI) as 
compared with extraglottic airways [21, 22]. In retrospec-
tive studies, though, successful ETI might also be indica-
tive of a generally higher skill-level of the EMS-personnel 
performing CPR. When using ETI during CPR, one needs 
to keep in mind that a high level of training is indispensa-
ble and that prolonged ETI-attempts, which go along with 
long interruptions of chest compressions, must be avoided. 
In a recent prospective, non-randomized trial, presence of 
a physician during CPR of OHCA-patients was associated 
with an impressively higher rate of survival than in patients 
being resuscitated by paramedics only [23], which confirms 
results of previous trials that observed higher survival rates 
in physician-staffed EMS [24]. Taken together, we can save 
thousands of lives each year if we manage to increase the 
likelihood of bystander-CPR and to optimize quality of 
ALS.
What to perform prior to ICU admission? Percutaneous 
coronary intervention before hypothermia
Hendrik Drinhaus and Bernd Böttiger Mild therapeutic 
hypothermia (MTH) and percutaneous coronary interven-
tion (PCI) are both established components of post-resus-
citation care after cardiac arrest, as recommended by the 
2008 Statement of the International Liaison Committee on 
Resuscitation (ILCOR) [25]. Already then, it was suggested 
that indication for early PCI be extended beyond obvious 
myocardial infarction (STEMI), given the high probability 
of significant coronary artery disease in OHCA patients 
[26]. Since then, several trials have underlined the benefi-
cial effects of early (<6 h after the event) PCI after OHCA 
also without STEMI [4, 27, 28]. Combination of PCI and 
MTH is feasible and does not necessarily lead to longer 
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door-to-balloon times [29]. Its effects on survival and good 
neurological outcome appear to be synergistic [30, 31]. 
Hence, modern post-resuscitation care includes hypother-
mia and early coronary intervention (unless a non-cardiac 
origin of cardiac arrest is assumed or confirmed). Induction 
of MTH is recommended to be started as soon as possible 
by the ERC guidelines. Meta-analyses of the existing data 
on very early and prehospital induction of MTH have not 
shown an improvement in survival [32]. In a recent large 
randomized controlled trial using large volumes of ice-
cold saline to induce MTH before arrival at the hospital, 
no difference in survival or neurological outcome could be 
found, but patients who received cold saline had a slightly 
higher risk of renewed cardiac arrest during transport to the 
hospital and of transient pulmonary oedema [33]. In the 
light of the findings presented hitherto, we deem it impor-
tant to stress the survival benefit of early PCI after cardiac 
arrest not only due to definite STEMI and to raise aware-
ness among EMS personnel to transport OHCA-patients to 
hospitals in which early PCI, as well as other components 
of post-resuscitation care, can and will be performed at 
any time. Prehospital cooling (at least by infusion of cold 
saline) on the other hand appears not to convey a benefit, 
maybe even a risk, and hence, not too much time and effort 
should be spent on aggressively lowering temperature dur-
ing transport using ice-cold saline solution. In any case, 
induction of MTH must not delay arrival at an appropriate 
hospital. It appears worth considering to include into the 
guidelines on resuscitation and post-cardiac arrest care a 
recommendation to treat patients after cardiopulmonary in 
specialized centres that can provide early PCI, MTH and 
targeted temperature management as well as expert ICU-
treatment wherever and whenever possible [34].
What to perform prior to ICU admission: is CT‑scan useful?
Alain Cariou Early identification of causes and conse-
quences of cardiac arrest is generally considered of impor-
tance, in order to prevent recurrence and subsequent clinical 
deterioration. Apart from coronary angiography, a brain and 
chest CT-scan can also be performed at admission, when an 
extra-cardiac cause is suspected and in the absence of an 
obvious pre-hospital etiology. In a recent study, this strategy 
was performed in 355 patients and provided a diagnosis in 
72 patients (20 %), mainly stroke and pulmonary embolism 
(PE) [35]. Early identification of brain damages can lead to 
major changes in therapy such as the use of anticoagulants. 
In addition, since the rate of subsequent brain death is very 
high in this subgroup, organ donation can be considered 
rapidly if an early diagnosis is achieved. Regarding PE, cur-
rent guidelines underline the potential benefit of identifying 
this curable cause of arrest [36]. Based on prodromes and 
clinical evidence, an algorithm can be proposed in order to 
manage early imaging after cardiac arrest (Fig. 4).
Thrombolysis in the treatment of cardiac arrest
Hendrik Drinhaus and Bernd Böttiger In non-traumatic 
OHCA, acute myocardial infarction (AMI) and pulmo-
nary artery embolism (PAE) account for approximately 
70–80 % of all cases [37]. Common feature of these aeti-
ologies is the obstruction of vital arteries by a blood clot. 
Dissolving these blood clots by administering fibrinolytic 
substances to re-establish circulation in the respective ves-
sel beds therefore appears to be a logical approach from 
a pathophysiological point of view. Several case-reports 
and case-series have shown impressive results in patients 
with presumed or documented PAE [38, 39]. Improvement 
of return of spontaneous circulation (ROSC) and survival 
Fig. 4 Algorithm for early imaging diagnosis after cardiac arrest
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rates in patients who received thrombolysis during CPR 
has also been observed in non-randomised observational 
trials [40, 41]. A large randomised, double-blind, placebo-
controlled trial—the TROICA-study—was therefore initi-
ated to systematically evaluate thrombolysis during OHCA 
of presumed cardiac origin, not limited to suspected pul-
monary artery embolism. In this trial, no difference with 
regard to ROSC or survival rates in an unselected OHCA-
population could be detected. Intracranial haemorrhage 
occurred more frequently in the tenecteplase-group [37]. 
Hence, no recommendation to administer fibrinolytics as 
a standard of care in all OHCA-patients could be gener-
ated from this trial. Accordingly, the current guidelines of 
the European Resuscitation Council recommend not to use 
fibrinolytics routinely during CPR. However, fibrinolytics 
should be considered if pulmonary embolism is the proven 
or suspected cause of cardiac arrest. In this case, cardio-
pulmonary resuscitation should be maintained for at least 
60–90 min after injection of the fibrinolytic, if necessary 
[42]. Taken together: if a coronary cause of cardiac arrest is 
assumed, fibrinolytic drugs should not be used and prompt 
coronary revascularisation, usually by percutaneous coro-
nary intervention, is the treatment of choice—even during 
ongoing CPR. Fibrinolytics must be considered if pulmo-
nary artery embolism is the suspected or proven cause of 
cardiac arrest.
CPR is better without epinephrine in cardiac arrest!
Kjetil Sunde Whereas there is clear evidence for improved 
survival with CPR and defibrillation during cardiac arrest 
management, there is today lacking evidence that any of 
the recommended and used drugs leads to any long-term 
benefit for the patients. Thus, until we have better drugs or 
combination of drugs, ALS can be performed without the 
use of drugs, and instead gains all focus on improving the 
tasks we know improve survival. Good-quality CPR, early 
defibrillation together with goal-directed post-resuscita-
tion care is way more important than giving drugs with no 
proven benefit [43]. More drug studies are indeed required, 
and future research needs to incorporate better diagnos-
tic tools to test more specific and tailored therapies that 
account for underlying aetiologies and individual respon-
siveness. We should expand our diagnostic capabilities 
exploring the feasibility of utilizing technologies such as 
capnography, near-infrared spectrophotometry (NIRS), VF 
analysis, and ultrasound assessment to allow targeted ther-
apy (while maintaining adequate CPR). When good quality 
of care and improved diagnostics have been ensured, more 
tailored drug approaches could eventually be tested based 
on underlying etiologies.
ECMO for cardiac arrest: ECMO is futile
Martin Dworschak Extended time periods of no and 
low flow after CA are generally associated with poor out-
come. Although return of spontaneous circulation can be 
achieved after more than 20 min of CPR, only few patients 
will survive with good functional outcome [44, 45]. By 
rapid deployment of ECMO in patients with refractory 
conventional CPR (CCPR) systemic blood flow can be 
maintained to prevent irreversible organ damage. The 
best results with extracorporeal CPR (ECPR) have been 
obtained so far in neonates and children when ECPR 
was instituted during in-hospital cardiac arrests that had 
short response times. The benefit of ECPR in adults being 
resuscitated for in- or OHCA is less clear. One major con-
founder is the fact that ECPR is frequently considered for a 
highly selected patient population (young age, ventricular 
fibrillation as the initial cardiac rhythm, witnessed arrests 
with immediate bystander CPR) only [46]. Nevertheless, 
quoted survival rates after ECPR [47] are either compa-
rable with those in CCPR patients [48] or slightly better, 
but this does not seem to impact on neurological outcome 
[46, 49]. Accordingly, in 2010 the American Heart Asso-
ciation did not recommend the routine use of ECPR [50]. 
Yet, it could be taken into consideration when it is readily 
available and the no-flow duration is brief. Furthermore, 
the conditions that led to the arrest should either be revers-
ible or amenable. Particularly in OHCA, however, most 
patients are neither young nor hypothermic or intoxicated 
and they do not present with a shockable rhythm; fewer 
CAs are witnessed and the quality of BLS/ALS is usually 
unknown. Another handicap in OHCA appears to be fast 
deployment of ECMO with quick institution of therapeu-
tic hypothermia [51]. Although ECPR seems to improve 
survival, especially after long-duration CPR, the rate of 
neurologically intact survivors still remains low. Future 
research should define criteria for the optimal indication of 
ECPR and criteria for ECPR as a bridge to LVAD, HTX, 
or organ procurement to guarantee efficient use of precious 
and scarce resources. Randomized controlled trials, as well 
as crucial analysis of uniformly reported CA data from reg-
istries would greatly facilitate decision-making.
Post‑resuscitation management: targeted temperature 
management
How to cool?
Fabio Taccone Several cooling methods, both invasive 
and non-invasive, are currently used to achieve target tem-
perature after post-anoxic brain injury. Invasive methods 
include the administration of intravenous cold fluids or 
the use of endovascular cooling catheters [52]. The use of 
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cold (4 °C) fluid infusion is cheap and easy-to-use, even 
in the pre-hospital setting. This method is generally rec-
ommended to initiate cooling in comatose survivors after 
CA, either alone or in conjunction with other cooling sys-
tems [53]. A 2-l bolus given over 30–60 min immediately 
after ROSC was associated with a mean decrease in core 
temperature of 1.3 °C [54]. This method is largely used 
also to induce hypothermia in the fields [33]. However, 
cold fluids are not effective to maintain target temperature 
[55] and, because of potential excessive volume-loading 
and reduced coronary perfusion pressure [56], have been 
recently associated with an increased risk of re-arrest and 
pulmonary oedema when given before hospital admission 
[33]. The endovascular cooling catheter contains a circu-
lating cold solution, which is maintained at a controlled 
temperature; this method can easily achieve a cooling rate 
of 1.5–4.5 °C/h [52]. Moreover, the use of an endovascular 
system reduced the variability of body temperature around 
the target value and increased the proportion of time that 
patients spent within the therapeutic temperature targets 
during the maintenance phase [57]. Main limitations are 
related to the time to insertion into a large vein, the need 
of a bedside heat exchanger with energy supply (i.e. lim-
ited used outside the ICU) and the potential risk of venous 
thrombosis or infection [58].
Non-invasive methods include external surface and 
ice packs or pads. Modern cooling blankets or fluid pads 
usually operate with a continuous temperature feedback 
mechanism, which reduced the risk of temperature vari-
ability and overcooling, and present a cooling rate around 
1.2–2.5  °C/h in CA patients [52, 59]. Unfortunately, 
these devices also depend on an external energy sup-
ply and it remains difficult to use them outside the ICU. 
Ice packs can be easily applied to different areas of the 
body, are inexpensive and are not dependent on an exter-
nal energy source; however, the cooling rate is extremely 
poor (<1 °C/h) and could expose patients to overcooling, 
as there is no feedback temperature control. Ice pads can 
provide a faster cooling rate (up to 3 °C/h) after CA, but 
they have been associated with thermal skin damage on 
the sites of application [60].
An attractive alternative to these methods is to induce 
brain hypothermia, especially because of the decreased 
risk of side effects associated with whole-body cooling. 
Cranial cooling cap devices placed around the head and 
neck can easily decrease tympanic temperature; how-
ever, they are mostly effective in children because of 
their favourable ratio of head-to-body surface area [61]. 
Nasopharyngeal cooling devices, which use volatile cool-
ant fluids via a specific nasal catheter, can rapidly reduce 
brain temperature with a concomitant reduction of core 
temperature around 1.0–1.5  °C/h [62]. These systems 
are quite safe, are not dependent on an external energy 
source and can be initiated even during cardiopulmonary 
resuscitation [63]. Alternatives methods for cooling could 
be continuous renal replacement therapy, peritoneal lav-
age and, in case of severe cardiogenic shock, the use of 
extracorporeal membrane oxygenation (ECMO) devices; 
however, these methods are particularly invasive and 
their use has been limited to very selected cases [64–66].
Finally, no prospective study has shown a clinical 
superiority of one method to another, while some retro-
spective reports suggest a better survival rate for endo-
vascular cooling when compared to surface cooling 
methods [67, 68]. Importantly, the endovascular catheter 
and modern surface devices have significant higher costs 
than intravenous fluids and ice packs [69]; however, their 
use was associated with an important reduction of nurse 
workload and improvement in patients’ care [70].
For how long?
Kjetil Sunde The precise description of patients that 
will benefit from therapeutic hypothermia (TH), or tar-
geted temperature management (TTM), the ideal induction 
technique (alone or in combination), target temperature, 
optimal maintenance and rewarming times have yet to be 
established. Independently of the cooling method chosen, 
TH is easy to perform, and without severe side effects or 
complications associated with mortality. As for the dura-
tion of TH/TTM, the majority of centers use 24 h as their 
treatment strategy; however, we are lacking of clinical data 
comparing different durations. Newborn asphyxial arrests 
are treated with TH for 72 h, with several RCTs proving its 
benefit compared to normothermia/fever. In a recent ani-
mal study, post-cardiac-arrest TH resulted in comparable 
improvement of survival and survival with good neurologic 
function when initiated within 4 h after return of sponta-
neous circulation. Interestingly, histological assessment 
of neuronal survival revealed a potentially broader thera-
peutic window and greater neuroprotection when TH was 
maintained for 48 versus 24 h [71]. However, this benefit 
was not seen in the neurological outcome evaluation. In a 
clinical registry study among approximately 1000 cooled 
comatose cardiac arrest patients, factors related to the tim-
ing of TH had no apparent association to outcome (Fig. 5).
Any evidence for non‑shockable rhythm patients?
Nicolas Deye According to international guidelines, 
therapeutic hypothermia (TH) might also benefit coma-
tose adult CA patients with spontaneous circulation after 
resuscitation from a non-shockable rhythm [72]. However, 
there is no large randomized controlled trial evaluating the 
clinical impact of TH in this situation. Using TH for non-
shockable CA patients is supported by only low level of 
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scientific evidence and extrapolation of data resulting from 
shockable rhythms. Consequently, the potential impact of 
TTM including TH-implementation remains controver-
sial for CA patients presenting with initial non-shockable 
rhythm [73, 74]. Treating such patients becomes a major 
health issue, as the proportion of these patients increases 
over decades while the proportion of OHCA patients 
resuscitated from shockable rhythms declines and now 
represents the minority of OHCA patients [75]. Prognosis 
of patients experiencing CA still remains poor. However, 
large registries reported recently for non-shockable CA 
patients hospitalized in ICU survival up to 26 %, favour-
able neurological outcome at 6 months of 22 %, and sur-
vival rate at 10 years after hospital discharge alive reaching 
43 % [76, 77].
The pro-con debate on the use of TH in non-shockable 
patients has been previously described [74]. Briefly, some 
argue in favour of the use of TH in non-shockable CA 
patients: (1) the pathophysiological processes responsi-
ble of post-anoxic (brain) damages seem independent of 
the initial rhythm (i.e. shockable versus non-shockable); 
(2) most of experimental and animals studies strongly 
support the use of TH in asphyxia and CA models irre-
spective of the initial rhythm; (3) with more than 10 
concordant large randomized controlled trials and meta-
analyses, TH initiated within 6  h and targeted to 32.5–
35.5  °C for 72  h is unequivocally beneficial on survival 
and neurological outcome in newborns who sustained 
asphyxia (with or without cardiopulmonary resuscita-
tion: CPR) and exhibit acidosis and/or neonatal hypoxic-
ischaemic encephalopathy [73, 74, 78]; (4) TTM with 
TH is potentially the unique available treatment to date 
prone to minimize brain damages and long-term dis-
abilities, and to increase survival without major sequelae 
in non-shockable CA patients [74]; (5) some observa-
tional, retrospective or prospective, but non-randomized 
clinical studies observed a benefit of TH in non-shocka-
ble CA adults patients, with one meta-analysis suggesting 
a reduced in-hospital mortality without improvement of 
the neurological outcome in these patients.
Conversely, the potential increased TH-related side 
effects are not in favour of the use of TH in non-shock-
able CA patients. Adverse events include the increased 
delay in time to recovery of consciousness leading to a 
prolonged delay to evaluate the neurological recovery. 
This delay seems mainly induced by the use of sedatives 
and neuromuscular blockers often required during the 
TH use, leading to a possible prolongation of mechani-
cal ventilation and hospitalization durations, and conse-
quently of ICU costs. The increased incidence of other 
main side effects, essentially pneumonia and sepsis, could 
be another explanation altering the risk/benefit ratio of 
TH, although neither firmly established nor related to the 
initial CA rhythm [74, 76, 79].
Additionally, several studies describing non-shockable 
CA patients have not shown significant prognostic effect 
of TH [74]. Most of the studies included in the first meta-
analysis evaluating this issue presented substantial risks 
of bias and a very low quality of evidence. Thus the ben-
eficial effect observed for in-hospital mortality was no 
longer significant when analysis was restricted to the two 
small RCTs available. Another meta-analysis similarly 
concluded that the group sizes for patients with asys-
tole or non-cardiac causes of CA were too small to draw 
conclusions. At least, several recent non-randomized 
controlled studies—after adjustment in some studies—
reported negative or even harmful TH-effects on out-
come in this population [74, 80–82]. Similarly, with a TH 
implementation in nearly 50  % of patients and a global 
hospital survival of 2  % in the non-shockable rhythm 
group, TH was not significantly associated with hospital 
survival after adjusting for other prognostic factors [75].
Beyond ethical considerations regarding the TH-
related futility/benefit ratio, some major issues remain 
unsolved regarding the ideal TTM in this specific 
population.
The correct selection of patients that could benefit or 
not from TTM or TH-implementations seems critical in 
this heterogeneous group, as well as the underlying co-
morbidities and severity of the post-resuscitation syn-
drome [74]. Indeed an initial non-shockable rhythm may 
represent: (1) either the first documented CA rhythm 
resulting from a severe non-cardiac aetiology with its 
own prognosis per se; (2) or the consequence of an initial 
shockable CA with a prolonged time to first CPR leading 
to prolonged ischaemic times, severe brain damages and/
or multiple organ failures. A non-prolonged time from 
collapse to return of spontaneous circulation (i.e. sum of 
the time to first CPR plus the duration of CPR) could be 
Fig. 5 Therapeutic hypothermia side‑effects and their categorization
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a relevant prognosis factor able to identify patients who 
may mostly benefit from cooling independently of the 
initial rhythm. Conversely in witnessed-OHCA patients, 
the more prolonged is the time from collapse to first CPR 
the better could be the TH-benefit after adjustment on 
other factors including the initial rhythm. The target pop-
ulation in non-shockable patient probably results from a 
complex balance between patients that can benefit from 
TH (i.e., those with TH-accessible brain damages with 
adequate durations of time to first CPR and CPR dura-
tions) versus those who do not (i.e., those with multiple 
organ failure or too severe prognosis that could lead to 
early death or early treatments withdrawal). Addition-
ally, the TH-implementation in non-shockable patients 
is often left at the bedside physician’s discretion in most 
studies evaluating this issue, and important bias should 
be introduced regarding the correct selection of patients 
[74, 83].
At last, the aetiology and/or mechanisms respon-
sible for fever are possibly a key issue to correctly 
evaluate patients able to receive a TTM or a TH imple-
mentation, especially after CA occurrence in non-shock-
able patients. In a large population of unselected ICU 
patients, fever was not always associated with a poor 
prognosis and control of fever was not always associated 
with better prognosis, with important differences exist-
ing between septic and non-septic patients [84]. Post-
CA syndrome often mimics a sepsis-like syndrome. The 
correct discrimination of patients who may benefit for a 
strict normothermic control, those who may benefit for 
a TH implementation targeted to 32–35 °C, versus those 
who may—or not—benefit for a fever control within the 
48–72 h after CA to avoid rebound hyperpyrexia, is the 
next step to optimize the temperature control after CA in 
the non-shockable population [74, 85].
The choice of the correct target temperature as the 
precise achievement of goal temperature seems also 
crucial in these patients. The recommended treatment 
for all post-CA patients is at present an early TH-imple-
mentation of 12–24  h targeted to 32–34  °C [72]. An 
adapted scheme of TTM could be of critical importance 
in non-shockable patients, regarding the optimal dura-
tion, speed cooling, level of temperature, therapeutic 
window, and rewarming rate of TTM, considering that 
the cerebral damages may be more severe in this popula-
tion [72, 74]. Interestingly, in the large recent TTM-trial 
including 20 % of patients presenting with an initial non-
shockable rhythm out of a total 939 enrolled patients, 
no difference were found between the 2 studied arm, 
i.e. 33 versus 36  °C applied for 28  h. The TTM-scheme 
included in both groups a gradual rewarming <0.5  °C/h 
to reach 37  °C, with tapering or discontinuation of the 
mandatory sedation at 36 h, and a maintenance of body 
temperature for unconscious patients <37.5 °C until 72 h 
after CA [86]. Similar results were herein observed in all 
pre-planned subgroups including analyses performed 
according to initial rhythm (i.e. non-shockable versus 
shockable), suggesting that “strict normothermia” tar-
geted to 36 °C should be an alternative in non-shockable 
rhythm CA patients.
This ongoing debate clearly underlines the need for a 
large multicentre study evaluating the effects of different 
scheme of TTM and TH in non-shockable CA patients 
after careful patients’ selection, including insights in sub-
groups according to the pathophysiology of the CA. To 
date, the indication for TH in non-shockable patients 
should be based using a case-by-case approach, whereas 
a TTM approach targeting strict normothermia remains 
reasonable for these patients.
Hypothermia‑associated complications
Alain Cariou Besides infections, several other adverse 
events such as arrhythmias, seizures, bleeding or thrombo-
sis, electrolyte and metabolic disorders, occur commonly 
in comatose patients treated in critical care units after out-
of-hospital cardiac arrest. These events may be related to 
the cause precipitating the cardiac arrest, the post-cardiac 
arrest syndrome or the critical care treatment. As it may 
affect many physiologic processes and responses, hypo-
thermia itself is commonly suspected to promote these 
events (Fig. 2) [87]. However, most of these events are 
probably not related to TH, as suggested by the results 
of a recent Cochrane systematic review that revealed no 
significant difference in reported adverse events between 
hypothermic and control patients [88]. Regarding meta-
bolic disorders, rapid changes in glycemia are possibly the 
most clinically relevant event that could be worsened by 
hypothermia [89, 90]. As it may worsen brain damages, it 
suggests minimizing glycaemic variations during the post-
resuscitation period. In addition, TH most often requires 
sedation, ventilation, and neuromuscular blockade, which 
may delay the possibility of neurological evaluation.
What is a real targeted temperature management: TTM 
at 36 °C
Hans Friberg In 2002, two landmark trials were pub-
lished showing that lowering body temperature to 33 °C 
improved neurological outcome and saved lives in coma-
tose survivors of out-of-hospital cardiac arrest [52, 91]. 
This therapy was rapidly adopted by international guide-
lines and not questioned until a systematic review using the 
GRADE methodology and trial sequential analysis showed 
that the quality of the evidence for treating cardiac arrest 
patients at 33 °C was low [86]. Criticism included the low 
number of enrolled patients and the fact that both trials had 
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weaknesses, including quasi-randomization, lack of power 
analysis and early stopping which was not adjusted for. 
Furthermore, patients in the control groups were treated 
according to standard care of that time which allowed fever 
[92].
This led to the design of a new trial, randomizing 
patients to two controlled temperatures, 33 and 36  °C 
[93]. The Target Temperature Management after Out-
of-hospital Cardiac Arrest trial (TTM-trial) included 
and randomized 950 patients in 27 months, almost three 
times the number of the two previous trials combined. 
Thirty-two sites enrolled patients in nine countries in 
Europe plus Australia. The TTM-trial differs from pre-
vious trials in several aspects, the most important one 
being that all patients received controlled temperature 
management avoiding fever in both intervention arms 
(Fig. 6). Other differences include a contemporary setting 
with improved pre-hospital care with a high bystander 
CPR rate, and improved hospital care in patients with 
ROSC. For example, two of three patients in the TTM-
trial received an early angiography (<24  h). Other qual-
ity criteria that were acknowledged in the TTM-trial, as 
opposed to previous trials, were that the design and the 
statistical analysis plan were published in advance. [93, 
94] In addition, prognostication of comatose patients was 
performed according to a strict and predefined protocol 
and the rules for decisions on withdrawal of life-sustain-
ing therapy (WLST) were transparent and published in 
advance [90]. The primary outcome was survival until 
the end of trial. A neurological assessment, using both 
the Cerebral Performance Category scale (CPC) and 
the modified Rankin Scale (mRS), was performed at 
6 months and was blinded.
In summary, the TTM-trial has sent a clear message 
to the medical community that no difference in survival 
(Fig. 7) or neurological outcome could be detected when 
comatose patients after cardiac arrest were treated at 
either 33 or 36 °C [86]. We can therefore conclude that a 
real target temperature management after cardiac arrest 
is a controlled temperature at either of the two tempera-
tures, both avoiding fever. This should be part of a bun-
dle of care, including treatment of acute coronary disease 
and contemporary and active intensive care.
Our rationale for changing to 36  °C is that this tem-
perature is closer to normal and less invasive, reducing 
known and unknown risks. The number and severity of 
adverse events in the two intervention arms did not dif-
fer in the TTM-trial, although there was a tendency 
towards less events in the 36°-arm (p  =  0.086). Treat-
ing the patients closer to normal temperatures allows 
for predictable drug effects, including those of sedatives 
and antithrombotic therapy. In a recently published post 
hoc analysis of the TTM-trial of the subgroup of patients 
in circulatory shock at admission, a higher mortality at 
ICU discharge was suggested in the 33  °C-arm (66 ver-
sus 44 %, adjusted p value 0.03) [95]. We cannot exclude 
that other subgroups may benefit from treatment at 36 °C 
or for that matter, from treatment at 33 °C. The optimal 
temperature, duration of temperature management and 
target population are yet to be defined.
Post‑resuscitation management: optimizing organ 
perfusion and metabolic parameters
Oxygen and carbon dioxide after cardiac arrest: friend or foe?
Nicolas Deye In CA patients, neurological injury is a 
major cause of mortality [72]. A first hypoxo-anoxia phe-
Fig. 6 Mean bladder temperature in the 33 and 36 °C intervention 
groups of the Target Temperature Management after Out‑of‑hospital 
Cardiac Arrest Trial (TTM‑trial), during the 36 h of temperature 
intervention. Temperature values are presented with 95 % confidence 
intervals. In the original publication, temperature curves displayed 
the means ± 2SD. From Wise MP et al. [179]. Reprinted with permis‑
sion
Fig. 7 The TTM‑trial included and randomized 950 comatose 
patients to either 33 or 36 °C. Probability of survival through the end 
of the trial and the number of patients at risk at each time point is 
presented. From Nielsen et al. [86]. Copyright © (2013) Massachusetts 
Medical Society. Reprinted with permission
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nomenon occurs initially during CA before and during 
CPR maneuvers. The ischemia–reperfusion syndrome 
occurring in the post-resuscitation phase after obtaining 
an ROSC can lead to secondary insults including oxidative 
stress with free radical formation or mitochondrial dys-
function [72, 96]. Oxygen (O2) and carbon dioxide (CO2) 
abnormalities can promote these insults. Targeted tempera-
ture management (TTM), including therapeutic hypother-
mia (TH) targeted to 32–34 °C, is one of the therapeutic 
measure improving prognosis and neurological outcome 
after CA. Induced hypothermia could minimize the CA-
related injuries by decreasing O2 free-radical production, 
mitochondrial dysfunction, brain O2 consumption [96]. 
Thus TH could minimize neuronal death and improve neu-
rological outcome and survival. However, hypothermia is 
associated with several arterial blood gas (ABG) modifica-
tions, mainly induced by the leftward shift of the hemo-
globin dissociation curve, increased O2 and CO2 solubility, 
modification of the pH regulation, with hypoventilation and 
hypometabolism, leading per se to hypoxia and hypocap-
nia. Iatrogenic dyscarbia incidence (hypo- or hyper-carbia) 
has been reported up to 69 % [97], hypoxia up to 63 % 
[98], and hyperoxia up to 41 % [99]. International guide-
lines mainly focused on potential hypocapnia and hypoxia/
hyperoxia harmful effects for CA patients [72, 100]. They 
advocate initial resuscitation with 100 % O2 ventilation to 
avoid hypoxia followed by a titration of O2 therapy target-
ing arterial O2 saturation levels between 94 and 96(−98) % 
especially during the initial post-CA period to avoid hyper-
oxia.
Beyond general detrimental effects such as decreased 
stroke volume, cardiac output and coronary blood flow 
and increased systemic vascular resistances, poten-
tial neurological harm of O2 therapy have been largely 
described [100, 101]. Hyperoxia can exacerbate cellular 
oxidative stress injury and mitochondrial dysfunction to 
key mitochondrial enzymes or mitochondrial lipids, leads 
to cerebral O2-related vasoconstriction with a decreased 
cerebral blood flow (CBF) and cerebral energy metabolism 
impairment. It can increase the neuronal lipid peroxida-
tion and protein oxidation, enhance O2 free radical for-
mation and reactive O2 species, or react with nitrite oxide 
to produce toxic metabolites (peroxynitrite, superoxide 
ion, hydrogen peroxide). All of this will finally participate 
to cell death. Despite several limitations or controversial 
results in specific experimental models [100–102], most 
animal studies have suggested that hyperoxia after CA 
could worsen neurological outcome [103].
In a retrospective cohort including 145 adult OHCA 
patients with available arterial O2 pressure (PaO2) on 
ABG sample during CPR attempts, an increased PaO2 
was associated with improved rate of hospital admission 
alive in multivariate analysis [104]. Incidence of hyper-
oxia defined as PaO2 >300 mmHg reached 14 %, whereas 
hypoxia was defined as PaO2 <60  mmHg. The potential 
deleterious effect of hypoxia during the resuscitative 
efforts has been also found in another recent retrospec-
tive study [100].
Most clinical studies depicting the O2 effects after 
ROSC from CA are methodologically of low level quality. 
The only small randomized clinical trial evaluating this 
issue found a significant decreased value of the Neuron 
Specific Enolase biomarker in favor of a normal level of 
PaO2 versus a high level PaO2 in the subgroup of patients 
without TH [105]. However, this result was not observed 
for the S100B Protein biomarker and in the whole cohort 
including the 28 patients regardless TH implementa-
tion. Hypoxia and hyperoxia harmful effects regarding 
in-hospital mortality and functional status were initially 
described in a large American registry in 2010 [98]. Sev-
eral issues have been pointed out for these studies: (1) the 
statistical methods (registries and databases versus scarce 
randomized studies, retrospective versus prospective 
studies, single center versus multicentre studies, adjust-
ment not usually performed to control for other poten-
tial confounders); (2) the definitions regarding hyperoxia 
thresholds (i.e. what precise level of PaO2 to choose?); (3) 
the different time-point measurements and the period of 
data collection (i.e. what value to consider between the 
first ABG, the ABG on admission, the ABG within the 
first hours or the first day after ROSC or CA, between 
the mean or median versus the maximal or minimal PaO2 
values or the worst PaO2 using worst (A-a) DO2 or the 
PaO2/FiO2 ratio?); (4) the associated treatments (i.e. TH 
versus the absence of TTM); (6) the best endpoint (i.e. in-
hospital mortality versus neurological outcome).
A recent meta-analysis concluded that hyperoxia in the 
post-resuscitation phase after ROSC was significantly 
associated with an increased in-hospital mortality [99]. 
Conversely, the poor neurologic outcome at hospital dis-
charge did not reach significance suggesting a possible 
lack of association or a review underpowered. However, 
these results need further confirmation because of its sig-
nificant heterogeneity (results were inconsistent in sub-
group and sensitivity analyses) and the limited number of 
studies analyzed (3 abstracts out of the 10 pooled studies 
were finally included). Since this review, two other stud-
ies describing a low hyperoxia incidence rate (3 and 6 %) 
have been published [106, 107]. The potential harmful 
effect of hyperoxia regarding mortality was not signifi-
cant. In only one of these 2 studies [106], hyperoxia was 
significantly associated with poor neurological outcome 
in the multivariate analysis, depicting a “V-shaped” rela-
tionship between probability of unfavorable outcome and 
the mean PaO2 value obtained from ROSC to rewarming.
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Cerebral autoregulation physiologically maintain a con-
stant CBF within a large range of mean arterial pressure 
[100, 108]. This relationship is modified by dyscarbia as 
cerebral perfusion depends on CO2. Hypercapnia leads to 
cerebral vasodilation and potentially increased intracra-
nial pressure, whereas hypocapnia leads to cerebral vaso-
constriction and potentially ischemia (decreasing PaCO2 
of 1 mmHg can decrease CBF up to 3 %). Ensuring physi-
ological CO2 tension in CA patients seems important to 
prevent worsening of the neurological status. Further-
more, impaired autoregulation has been described in 
some brain-injured areas, in some TH-treated patients, 
and inconstantly in CA patients. Recommendations 
in resuscitated CA patients suggest a PaCO2 target of 
40–45 mmHg during the post-ROSC period in this popu-
lation of brain-injured patients regardless of TH use [72, 
100]. In a retrospective single-center study implementing 
TH in 41 %, hypocapnia (defined by PaCO2 ≤30 mmHg), 
hypercapnia (PaCO2 ≥50  mmHg), and association of 
both dyscarbia occurring within the first 24  h after 
ROSC were all independently associated with poor neu-
rologic outcome at hospital discharge [97]. An observa-
tional multicenter registry recently enrolled 16.542 adult 
CA patients TH-treated in 39  %. Increased in-hospital 
mortality and rate of poor outcome were observed in 
the hypocapnia group compared to normocapnia after 
adjustment for illness severity and propensity score [109]. 
Conversely, hypercapnia (PaCO2 ≥45 mmHg) within the 
first 24  h after admission was independently associated 
with similar in-hospital mortality and a higher rate of dis-
charge home among survivors. In a smaller study of TH-
treated patients, hypocapnia but not hypercapnia was 
independently associated with an increased risk of in-
hospital death [106]. A “U-shaped” relationship between 
the mean PaCO2 and the in-hospital mortality was found 
with the best survival observed for the normocapnia 
group (35–45  mmHg). No association between hypo- 
and hyper-capnia with poor neurologic outcome were 
observed. Another recent multicenter and prospective 
study applying TH in 71 % defined PaCO2 as “low” when 
<30 mmHg, “middle” when 30–37.5 mmHg, “intermedi-
ate” when 37.5–45 mmHg, and “high” when >45 mmHg 
[107]. Patients with poor versus good outcome had simi-
lar highest, mean and lowest PaCO2. The mean 24-h 
PaCO2 and the time spent in PaCO2 >45 mmHg regard-
less TH-implementation were independently associated 
with better 1-year good outcome. However, same criti-
cisms can be made for all these studies than those made 
above regarding statistics, threshold, data collection, or 
treatments. To date mainly because of paucity of data on 
this issue, no clear thresholds have been found regard-
ing the harmful impact of hypo- or hyper-capnia after 
CA. Whereas hypocapnia seems consistently associated 
with worse outcome, hypercapnia is not [100]. The man-
agement of PaCO2 after CA by using specific mechanical 
ventilation strategy could influence the outcome of these 
patients especially during TH. In a recent retrospective 
study focusing on initial post-CPR mechanical ventila-
tion settings minute ventilation was weakly correlated 
with the initial PaCO2 [110]. Normocapnia alone (31–
49  mmHg) was again associated with a better favorable 
neurological outcome.
ABG measurements performed at 37  °C are sec-
ondarily expressed either as temperature-corrected or 
uncorrected according to biochemical centers [108]. 
Substantial discrepancies can be related to these meth-
ods: PaO2 =  100 mmHg at 37  °C becomes 79 mmHg if 
corrected at 33  °C, when PaCO2 =  36  mmHg becomes 
30 mmHg at 33 °C. There are no clear recommendations 
regarding the ventilation strategy to be used in resusci-
tated CA patients despite such differences. Normocap-
nia in hypothermic patients can be achieved according 
to two different mechanical ventilation strategies: α-stat 
versus pH-stat. In the α-stat strategy ventilation is set to 
achieve physiological arterial CO2 tension measured at 
37°, unadjusted to the patient’s temperature, whereas in 
the pH-stat strategy ventilation is set to achieve physi-
ological arterial CO2 tension measured at the patient’s 
actual temperature. The latter strategy leads to a relative 
hypoventilation compared to the α-stat strategy. Using 
either α-stat or pH-stat strategy to guide normocapnia 
after CA remain open to discussion. In the recent mul-
ticenter Finnish study focusing on ABG abnormalities 
after CA, 13 ICUs used temperature-correction; whereas, 
eight did not [107]. Two recent exploratory studies in 
TH-treated CA patients compared either a “lower versus 
upper threshold normocapnia” (32 versus 45 mmHg) or 
the α-stat versus the pH-stat strategies while maintaining 
a PaCO2 target level between 36 and 42 mmHg. The first 
study showed that the “lower threshold normocapnia” 
induced decreased internal jugular vein O2 saturation 
and CBF mean velocity suggesting an increased risk of 
cerebral ischemia. The second study found that the alpha-
stat strategy increased jugular vein desaturation and cer-
ebral O2 extraction and decreased transcranial Doppler 
cerebral velocities in survivors but not in non-survivors.
In summary, dyscarbia especially hypocapnia should 
be associated with an increased harm after CA leading to 
increased unfavorable outcome or in-hospital mortality. 
Conversely O2 seems a two halves phenomenon with: (1) 
a former deleterious effect of hypoxia during resuscita-
tion efforts, the potential benefit of hyperoxia implying 
more evaluations; (2) followed by a deleterious effect of 
both hypoxia and hyperoxia after ROSC in the post-CA 
phase. To date because O2 and CO2 derangements have 
no obvious benefit, aiming at normoxia and normocapnia 
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after CA are potentially two very easy targets to achieve 
in post-resuscitation care bundles. Meanwhile all stud-
ies describing ABG parameters in TTM- or TH-treated 
CA patients should actually emphasize the strategy used, 
either a temperature-corrected or a non-corrected strat-
egy to more precisely evaluate potential thresholds.
Other means of cardio‑ and neuro‑protection
Fabio Taccone Heart and brain protection strategies aim 
to prevent or attenuate disease progression and secondary 
injuries by halting or at least slowing the loss of cardio-
myocytes and/or neurons [111]. Although many pathologi-
cal mechanisms, including endothelial damage and tissue 
hypoperfusion, inflammation, impaired mitochondrial res-
piration with induction of reactive oxygen species, calcium 
overload or excitotoxicity, are common in both cardiac and 
neurological injury following CA [112], some drugs may 
present a more specific organ protection or have a lower 
brain penetration, thus acting especially on the cardiac tis-
sue. Many therapeutic agents have been shown to be effec-
tive in protecting the heart and/or the brain in animal mod-
els of global or local ischemia [113]; nevertheless, these 
findings were flawed because of the differences between 
the experimental setting and the clinical scenario (i.e. 
absence of co-morbid diseases and need for anesthetics in 
animal studies), the low mortality rates or the administra-
tion of the specific drug before the development of injury 
(i.e. pre-treatment approach).
A promising approach to reduce brain excitotoxic-
ity (i.e. excessive extracellular glutamate levels) could be 
the administration of intravenous magnesium or inhaled 
noble gases (i.e. xenon or argon). In two studies, magne-
sium administration did not result in a better survival or 
neurological outcome for CA patients [114, 115]. How-
ever, hypothermia was not used in these studies, while 
the combination of magnesium with cooling procedures 
has been shown to result in the highest neuroprotective 
effects [116]. Importantly, many questions remain unan-
swered on the optimal timing to initiate magnesium per-
fusion, optimal dosing and circulating levels and potential 
side-effects, which may explain the negative results of 
magnesium therapy after subarachnoid hemorrhage and 
traumatic brain injury [117, 118]. Noble gases have been 
proved to reduce the extent of neurological damage after 
ischemia in animal models of CA [119, 120]. The admin-
istration of Xenon was also feasible in the human setting, 
reporting both no adverse events and an improvement of 
cardiovascular function after CA [121]. Unfortunately, we 
still do not have any human data describing the potential 
neurological benefits of such treatment.
Mitochondrial dysfunction could be attenuated by the 
administration of erythropoietin (EPO), the principal 
hematopoietic hormone regulating erythropoiesis, which 
shows also anti-apoptotic, anti-inflammatory and anti-oxi-
dant properties [122]. In a swine model of VF, high-dose 
EPO administration during CPR reduced post-resuscita-
tion myocardial dysfunction and improved cardiac func-
tion [123]. However, post-ischemic EPO administration 
in rats exposed to CA exerted no protective effect on hip-
pocampal neurons [124]. One human study has compared 
the effects of 90.000 UI of EPO given during CPR to an 
historical matched control group [125]. The EPO group 
had higher rates of ROSC (92 versus 53 %, p = 0.006) and 
hospital survival (54 versus 20 %, p =  0.011) when com-
pared to the control group. In another study [126], EPO 
therapy was associated with a trend towards higher full 
neurological recovery (55 versus 38 %) when compared to 
an historical cohort. Unfortunately, a recent unpublished 
randomized clinical trial (RCT) found no benefits of EPO 
administration on comatose survivors after CA when 
compared to placebo (Cariou et al.—presented at the 27th 
ESICM congress—Barcelona, October 2014).
Reperfusion injury leads to mitochondrial dysfunc-
tion also through the opening of a nonspecific pore in 
the inner mitochondrial membrane, known as the mito-
chondrial permeability transition pore (MPTP) [127]. 
This phenomenon causes the loss of ionic homeostasis 
and ultimately cell swelling and death. The inhibition of 
the MPTP opening may provide some protection against 
reperfusion injury; importantly, this may be mediated by 
a direct interaction of cyclosporine A (CsA) with a pro-
tein located on the MPTP, called cyclophilin-D [127]. In 
a murine model of CA, CsA was effective in reducing 
myocardial dysfunction when given at the onset of resus-
citation but not after ROSC [128]. In one human study 
conducted in patients suffering from acute myocardial 
infarction, the administration of a 2.5 mg/kg bolus of CsA 
before percutaneous coronary intervention was associ-
ated with a significant reduction in biomarkers of myo-
cardial injury (i.e. troponin I) and the extent of ischemic 
areas on cardiac magnetic resonance imaging [129]. 
Nowadays, no clinical studies have evaluated the effects 
of CsA on the neurological recovery of CA survivors yet.
Also, mitochondrial dysfunction can be modulated 
through the nitric oxide (NO)-related pathways; NO 
inhibits ROS-producing enzymes and directly scavenges 
ROS production [130]. Other potential beneficial effects 
are the direct vasodilation of coronary arteries, which 
could improve cardiac function in this setting. Experi-
mental models have suggested a protective role of intra-
venous NO-donors or inhaled NO both on cardiac and 
neurological function after CA [131, 132]. Unfortunately, 
only one pilot study showed the feasibility and safety of 
low-dose nitrite infusion in cardiac arrest survivors, but 
did not report any improvement in outcome [133].
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Finally, recent data suggest that the early administration 
of corticosteroids after in-hospital CA was associated 
with an increased survival rate and reduced occurrence 
of extra-cerebral organ failures [134]; whether these 
effects were secondary to an anti-inflammatory effect or 
the treatment of a relative adrenal insufficiency [135], it 
remains to be further evaluated. Similarly, abnormalities 
of peripheral microcirculation, similar to those found in 
septic patients, have been described after CA [136]; the 
pathophysiology of such alterations as well as their role 
on patients’ outcome and the various therapeutic options 
to manipulate the microvascular flow have to be better 
characterized in future studies.
Neurological assessment of brain damages
Minimal consciousness: classification and prognosis in CA 
patients
Steven Laureys and Didier Ledoux Successful resuscita-
tion after cardiac arrest or cerebral hypoxia can have an 
extremely wide variety of functional and cognitive conse-
quences, ranging from transient cognitive or motor dys-
function lasting several weeks or months; to awakening 
after coma in a state of unawareness or inability to com-
municate lasting months to years or decades (e.g. as seen 
in vegetative or minimally conscious states) [137]. At pre-
sent, the medical and economic impacts of differences in 
clinical management (including therapeutic hypothermia), 
care pathways and disparate health policies within Europe 
remain unclear.
Figure  8 illustrates the timeline of events that may 
occur after anoxic coma. When cerebral hypoxia leads to 
a prolonged loss of consciousness (lasting >2 h to differ-
entiate from syncope), the patient is considered to be in 
coma. Patients in coma will never open the eyes, even if 
stimulated by a loud noise or intense noxious stimulus, 
and will only show reflex movements. Coma will not last 
longer than a couple of days to weeks. Most patients who 
show good recovery will rapidly show signs of conscious-
ness and functional communication. Some patients, 
however, will evolve to brain death (i.e., irreversible 
coma with absent brainstem reflexes) and organ dona-
tion should be discussed [138]. Many patients will remain 
with some brainstem function (i.e., will not be brain 
death), but clinical and complimentary testing shows that 
there is no reasonable chance for a meaningful recovery 
and the decision is made to withhold or withdraw treat-
ment. In these cases, organ donation after cardiac death 
can be discussed.
Patients who survive their coma may awaken (i.e., open 
the eyes) without any behavioural sign of consciousness 
(i.e., only show reflex or automatic movements), a condi-
tion coined “persistent vegetative state” or “unresponsive 
wakefulness syndrome” (PVS/UWS) [139] or without 
recovery of functional communication or functional 
object use, a condition referred to as “minimally con-
scious state” (MCS) [140]. In contrast to coma, such 
chronic disorders of consciousness can last for many 
months to years and at present there are no reliable epi-
demiological data regarding these challenging patients. 
The heterogeneous MCS group is subcategorized in 
MCS—when patients only show non-reflexive behav-
iour such as eye tracking, orientation to pain or contin-
gent behaviour to specific stimuli (e.g. smiling exclusively 
in the presence of a family member) and MCS+ when a 
reproducible (albeit often inconsistent) response to com-
mand can be observed [141].
When patients remain in PVS/UWS for over 3 months 
after the cardiac arrest, the condition is considered irre-
versible and life-sustaining treatment (i.e., artificial 
hydration and nutrition) may be considered as futile and 
hence be withdrawn. At present, the chances of recovery 
after post-anoxic MCS are considered to be better than 
for PVS/UWS but remain ill defined. Many patients who 
recover from coma or related disorders of consciousness 
will show cognitive dysfunction and may remain insti-
tutionalized or dependent of others for many activities 
of daily living, but few reliable data exist regarding their 
remaining quality of life.
Recent advances in automated clinical EEG analysis 
[142], combined EEG transcranial magnetic stimulation 
studies [143] and structural and functional neuroimaging 
have permitted to better document the clinical diagnosis 
[144] and levels of consciousness in patients with severe 
post-anoxic encephalopathy [145]. Several studies also 
show their value in predicting the chances of recovery 
after cardiac arrest (e.g., the assessment of EEG reactiv-
ity [142]; the quantification of white matter damage using 
Fig. 8 Timeline of events that may occur after anoxic coma
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MRI diffusion tensor imaging [146] or PET imaging of 
residual cortical metabolism [147].
At present, there are no evidence-based guidelines 
regarding the treatment of patients with chronic anoxic 
disorders of consciousness [148]. In terms of noninvasive 
intervention, transcranial direct current stimulation has 
recently been shown to be of potential interest [149]. A 
better understanding of the temporal dynamics of pos-
sible residual neural plasticity following anoxic coma 
and related conditions will permit to improve their clini-
cal management (including treatment for possible pain 
perception [150]) and to rationalize our medical inter-
ventions [151] acute and chronic care pathways and end-
of-life decisions [152].
Clinical tools
Mauro Oddo The ideal tool for coma prognostication is 
the one yielding the lowest false-positive rate (FPR) for poor 
outcome. The definition of FPR is 1—specificity, whereby 
the “perfect” predictor would allow 100 % (i.e. 1.0) speci-
ficity and an FPR for poor outcome of 0 and limit as far 
as possible the risk of false predictions. Clinical exami-
nation comprises tools for the assessment of neurological 
responses/reflexes, including the Glasgow Coma Scale 
(GCS), brainstem reflexes and the comprehensive Full Out-
line of Unresponsiveness (FOUR) score. Clinical examina-
tion is an essential step for coma prognostication after CA 
[153]. However, clinical examination may be misleading, 
partly because of the effect of mild induced hypothermia 
and sedation on neurological responses. In particular, using 
the motor component of the GCS, it was found that motor 
response to pain may be delayed up to 5–6 days following 
CA [154]. Motor reaction to pain no better than extension 
indeed yields an unacceptably high FPR (10–20 %) for poor 
prognosis [155]. Apart from GCS, the assessment of brain-
stem reflexes (pupillary and corneal reflexes in particular) is 
crucial. Corneal and pupillary reflexes have very high speci-
ficity: bilaterally absent pupillary/corneal reflexes yield an 
FPR <1–2 % for poor prognosis, while their FPR for good 
prognosis is relatively high (40–50 %) [155].
The predictive value of pupillary reactivity is under-
lined by recent systematic meta-analyses [155, 156]. In 
this setting, newly available automated infrared pupil-
lometers hold great promise, because they allow quan-
titative measurement of the pupillary response. One 
single-center study recently showed quantitative pupil-
lometry is superior to standard pupillary examination for 
post-CA coma prognostication and performs comparably 
to electro-physiological exams (including EEG and SSEP) 
[157].
In summary, careful and complete neurological 
examination is the first and still valid tool for coma 
prognostication [158]. Clinical tools should be inte-
grated into a multimodal approach, which ideally also 
include electrophysiology (EEG reactivity and/or SSEP) 
and blood biomarkers (e.g. NSE). Using this multimodal 
approach, prediction of 3-month survival and neurologi-
cal outcome might approach 90 % accuracy [159]. Appli-
cation of such approach is supported by several recent 
independent studies and can be recommended in ICU 
practice [160].
New electrophysiological tools: continuous and simplified 
electroencephalography (aEEG)
Hans Friberg Electroencephalography (EEG) is a com-
monly used method for identification of seizures and for 
estimation of prognosis in comatose survivors after car-
diac arrest [161]. Limitations with an EEG-investigation 
include its sensitivity to sedatives and the fact that a single 
conventional EEG depicts the actual status during a limited 
time, commonly 20–30 min. Another problem has been 
the lack of consensus regarding EEG terminology and the 
absence of a uniform classification system, a problem that 
may be resolved by implementation of a standardized criti-
cal care EEG-terminology as recently proposed [162].
EEG-patterns that are strongly associated with a poor 
outcome after cardiac arrest and considered “malignant 
patterns” include a generalized suppression to <20  µV, 
burst-suppression pattern with generalized epilepti-
form activity, or generalized periodic complexes on a flat 
background [163]. In addition, a non-reactive EEG back-
ground pattern after rewarming from hypothermia treat-
ment has been found to be a predictor of poor outcome 
[164]. A reactive EEG-pattern on the other hand, and a 
return of a continuous EEG background pattern after 
cardiac arrest are both strongly associated with recovery 
and a good outcome [163, 164].
Continuous EEG (cEEG) provides dynamic information 
and can be used to monitor evolution of EEG-patterns 
and to detect seizures in the postischemic brain [165]. 
A traditional multichannel montage is commonly used 
in adult ICUs, while a simplified EEG-montage with few 
channels and trend analysis is more common in neonatal 
ICUs [166]. In order to reach general use, cEEG needs to 
be simple, possible to apply bedside and cost-effective.
We applied aEEG in consecutive cardiac arrest patients 
[167]. The aEEG curve facilitates rapid surveillance of 
extended time periods, but interpretation of patterns is 
done on the original EEG-tracings, one from each hemi-
sphere. The relative simplicity of cEEG with a reduced 
montage and aEEG trend analysis makes it attractive to 
generalists in the ICU. It is applied bedside by the ICU-
staff (registered nurse) and data are linked to the neu-
rophysiologists, who will assess the collected data on a 
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regular basis and on demand. In order to facilitate for 
clinicians, four dominating EEG-patterns after cardiac 
arrest were identified and described (Fig.  9) [167]. Our 
experience is that cEEG with a simplified montage and 
aEEG trend analysis is well suited to follow transitions 
in background patterns and has acceptable sensitivity to 
detect clinically relevant electrographic seizures. A return 
of a continuous EEG-pattern at normothermia is an early 
and strong prognostic indicator with a positive-predictive 
value for a good outcome of 0.87 (95 % CI 0.76–0.94) while 
other patterns at normothermia indicate a poor prognosis 
with a negative predictive value of 0.91 (95 % CI 0.76–0.98) 
[167]. The clinical benefit of treating electrographic seizure 
activity after cardiac arrest is yet to be proven, but simpli-
fied cEEG is a reasonable routine method to diagnose sei-
zure activity and to guide treatment.
In conclusion, simplified continuous EEG (cEEG) with 
trend analysis (aEEG) is a feasible and probably cost-
effective method to improve care after cardiac arrest 
[168]. Collaboration with neurologists and neurophysiol-
ogists and education of staff are keys to success. We fore-
see that simplified cEEG will be part of routine bedside 
monitoring of comatose survivors after cardiac arrest in 
the near future.
Neurological assessment in the long‑term follow‑up 
after cardiac arrest
Stephane Legriel Half the survivors after CA have 
long-term follow-up cognitive impairment affecting pref-
erentially memory and executive functioning, anxiety, 
depression, and finally quality of life. Surprisingly, there 
is no prospective study with extensive neuropsychological 
assessment and longitudinal follow-up allowing to confirm 
these retrospective data [169]. Moreover, the era of thera-
peutic hypothermia may have changed not only long-term 
outcomes, but also its early prognosis assessment [170]. 
Thus, three important questions can be raised.
What tools do we use to describe the long-term out-
come and are these tools sensitive? Whereas a recent 
review demonstrated a broad heterogeneity in the out-
come measures utilized in clinical trials, the Cerebral 
Performance Category (CPC) score is the recommended 
measurement of long-term outcome after CA [170]. The 
question of reliability of the CPC score has been evalu-
ated in several studies. There was a strong association 
between the CPC score at hospital discharge and long-
term outcome. Moreover, the CPC score demonstrated 
good correlation with various neuropsychological evalu-
ations in extensive cognitive battery tests, memory tests, 
adaptative behavior and quality-of-life evaluations. Thus 
the CPC could be considered as a gross indicator of long-
term functional outcome after CA.
How could we evaluate the outcome during the long-
term follow up? According to the World Health Organi-
zation guidelines, evaluation of health after CA should 
associate body functions and structures, with physical 
examination and cognitive functions, activity and partici-
pation, personal factors such as anxiety and depression, 
Fig. 9 A simplified electroencephalogram (EEG) with two original EEG curves (lower panel), in combination with an amplitude integrated EEG 
(aEEG) trend curve (upper panel). Four dominating EEG patterns after cardiac arrest are shown: a flat, b suppression‑burst, c continuous and d elec‑
trographic status epilepticus. From Friberg et al. [161]. Reprinted with permission
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and so quality of life (Fig. 10) [171, 172]. The American 
Academy of Clinical Neuropsychology recently rec-
ommended evaluation of the following items during a 
neuropsychological evaluation: intellectual function-
ing, attention and executive functioning, memory and 
learning, language and communication, visual–spatial 
cognition and visual–motor praxis, motor and sensory 
function, mood, conduct, personality, quality of life, 
adaptative behavior (activities of daily living), social–
emotional awareness and responsivity, psychopathology 
(psychotic thinking or somatization), motivation and 
effort [173]. Thereby, a formal neuropsychological evalu-
ation covers the whole spectrum of objectives of health 
evaluation.
What approach should we use to make an early prog-
nosis of long-term outcome? All the parameters provided 
in 2006 by the American Academy of Neurology for pre-
diction of outcome in comatose survivors after cardio-
pulmonary resuscitation have been challenged since the 
application of therapeutic hypothermia. Predictors based 
on clinical examination within 72 h after CA have dem-
onstrated higher false-positive rates [164]. Exceptional 
survivors have been described despite bilateral absence 
of N20 waves in median nerve somatosensory evoked 
potentials. Neuron Specific Enolase demonstrated vari-
able cut-off values associated with poor outcome ranging 
from 25 to 49.5 ng/mL on day 2 after cardiac arrest, with 
one survivor with an NSE value of 110 ng/mL. On day 3, 
variability was greater ranging from 10.6 to 97  ng/mL. 
Protein S100B was also associated with variability on day 
1 after CA [156]. Postanoxic status epilepticus has been 
demonstrated as an independent factor associated with 
poor outcome in retrospective and prospective studies 
[174, 175], but survivors with good long-term functional 
outcome have been described in 6 % of cases [175]. Con-
tinuous background pattern and reactivity during TH or 
normothermia has been associated with recovery and 
EEG plays now an increasingly important role in prog-
nostication of coma after CA. Thus, continuous EEG has 
been suggested to assist with prognostication of coma 
after CA [176]. Finally, literature data clearly favour a 
multimodal approach of prognostication after CA.
In conclusion, there is a broad variability in tools used 
for evaluation during the long-term follow and a lack of 
standardization. The cerebral performance category scale 
is an efficient but imperfect surrogate tool to describe 
long-term outcome after CA. The neuropsychological 
evaluation seems able to cover the whole spectrum of 
objectives of health evaluation needed to evaluate the 
long-term outcome. Early prognosis of long-term out-
come at the era of therapeutic hypothermia should be 
based on a multimodal approach in order to minimize 
false predictions.
Public healthcare
Stopping cares leads to organ donation?
Philippe Hantson There is still currently a shortage of 
organs for transplantation and accordingly, different strat-
egies have been developed, including the possibility of 
organ donation after cardiocirculatory death (DCD) as 
opposed to donation after brain death (DBD). Following 
the Maastricht workshop on non-heart beating donation 
in 1995, several categories of donors have been identified, 
but the acceptance of such procedures still varies largely 
among the different European countries. There is no doubt 
that the ratio DCD/DBD will continue to increase over 
time.
The ICUs are mainly concerned by categories II (unsuc-
cessful resuscitation) and III (awaiting cardiac arrest). 
Category III is a controllable situation that could be man-
aged either in the ICU or in the operating room. The pos-
sibility of organ donation under category III is also linked 
to ethical discussions regarding the management of the 
“end of life”, with a clear distinction between the concepts 
of euthanasia and withdrawal/withholding of some spe-
cific cares [177].
In contrast to DBD where specific protocols are now 
well accepted, there is a great variability for the DCD 
protocols regarding the criteria for the determination of 
death, but also for the definition of the “no-touch” period. 
This latter corresponds to the time period between deter-
mination of death and initiation of organ procurement, 
and should be theoretically kept as short as possible in 
order to prevent warm ischemia.
Fig. 10 Assessment of health condition in the long‑term follow‑up 
after cardiac arrest (adapted from World Health Organization [171])
Page 18 of 24Kudenchuk et al. Ann. Intensive Care  (2015) 5:22 
The main ethical difficulties are related to the perceived 
possibility of conflict of interest for the ICU physician 
who in one hand could take the decision to withdraw 
or withhold some specific care, and in a next step could 
also be authorized to take the decision of organ donation 
in the same patient. The separation (in time and space) 
between the two processes is absolutely mandatory. 
There is a need of full confidence between all the mem-
bers of the ICU staff taking care of the patient, so that 
each individual could be convinced that the treatment-
withdrawal decision is always made independently from 
any considerations about the potential of subsequent 
organ donation.
Another difficult ethical issue is the dying process itself. 
It remains difficult to predict the time to death by circu-
latory arrest after the withdrawal of the life-sustaining 
treatments. When organ donation is not considered, the 
patient is dying in the ICU, while in case of DCD, death 
will occur in the operating room, with ideally a short 
period of hypotension in order to prevent organ damages. 
But in fact, the dying process has already started several 
hours or days before the final decision in the ICU. The 
vision that the DCD procedure could hasten the patient’s 
death is not totally true, but there are still different per-
ceptions among the ICU physicians. Some of them feel 
that when comfort therapy with potent sedatives and 
analgesics (“palliative sedation”) is started in the ICU, the 
priority is to give a lot of time to the family to accompany 
the dying person. Other ICU physicians or even scientific 
societies consider that shortening the dying process with 
use of medications may sometimes be appropriate, even 
in the absence of discomfort, and can actually improve 
the quality of dying. Most of the families express the 
opinion that the priority should be that the patient would 
die peacefully, the duration of the dying process being of 
secondary importance. This is a key issue in the debate 
“taking care of the patient or taking care of the organs?” 
[178].
Finally, the wishes expressed by the patient (antici-
patively) or by the relatives have clearly to be taken 
into account. The treatment-withdrawal modalities will 
clearly be also be influenced by these opinions. When the 
decision is made to stop the cares in the operating room, 
it is with the objective that cardiocirculatory death would 
occur in a delay shorter than one hour and that the pro-
cedure of donation would be successful.
In conclusion, organ procurement under Maastricht 
III category will remain a sensitive issue as no protocol 
is widely accepted. Each centre has the responsibility to 
initiate the debate between all the participants involved 
in critical care and organ transplantation. The main per-
ceived risk is the abolition of the frontier between the 
cares orientated to the patient and the cares given to the 
organs.
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